Novo Nordisk A/S (NYSE:NVO) shares fell as much as 8% in Thursday trading after news emerged about a competitor’s successful drug trial.

Some of the best stocks to buy could be those falling the most. Zaven Boyrazian explores the worst-performing US shares for ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic benefits through a unique fat-blocking mechanism. However, its high ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic ...

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

In an astonishing interview, U.S. Treasury Secretary Scott Bessent blamed the stock market plunge on China's DeepSeek versus President Trump's tariffs.

Denmark’s benchmark stock index has fallen 21% from its September high, making it the first major European index to enter a bear market as tariff-related risks and a slump for Novo Nordisk A/S weigh.

Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for ...

Then the company released disappointing weight loss results for its highly anticipated CagriSema product (22.7% actual weight ...